Transgenic ResearchCancer BiologyPeer-reviewed journal article
Development of a new flippase-dependent mouse model for red fluorescence-based isolation of KrasG12D oncogene-expressing tumor cells
Dušan HrčkulákiD, Jakub OnhajzeriD, Michaela Krausová, Monika Šťastná, Vı́tězslav Křı́žiD, Lucie JanečkováiD, Vladimír KořínekiD
Abstract
Proto-oncogene KRAS, GTPase (KRAS) is one of the most intensively studied oncogenes in cancer research. Although several mouse models allow for regulated expression of mutant Kras, selective isolation and analysis of transforming or tumor cells that produce the Kras oncogene remains a challenge. In our study, we present a knock-in model of oncogenic variant KrasG12D that enables the "activation" of KrasG12D expression together with production of red fluorescent protein tdTomato. Both proteins are expressed from the endogenous Kras locus after recombination of a transcriptional stop box in the genomic DNA by the enzyme flippase (Flp). We have demonstrated the functionality of the allele termed RedRas (abbreviated KrasRR) under in vitro conditions with mouse embryonic fibroblasts and organoids and in vivo in the lung and colon epithelium. After recombination with adenoviral vectors carrying the Flp gene, the KrasRR allele itself triggers formation of lung adenomas. In the colon epithelium, it causes the progression of adenomas that are triggered by the loss of tumor suppressor adenomatous polyposis coli (Apc). Importantly, cells in which recombination has successfully occurred can be visualized and isolated using the fluorescence emitted by tdTomato. Furthermore, we show that KrasG12D production enables intestinal organoid growth independent of epidermal growth factor (EGF) signaling and that the KrasG12D function is effectively suppressed by specific inhibitor MRTX1133.
- organism: mouse
- research focus: cell type annotation
- research focus: cancer & tumor microenvironment
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 1
- FWCI
- 0.24
- Field percentile
- 36th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mouse models for pancreatic ductal adenocarcinoma are affected by the cre-driver used to promote KRASG12D activation.
F. Mousavi, J. Thompson, … F. Bednar·bioRxiv·Sep 12, 2023
- An in vivo KRAS allelic series reveals distinct phenotypes of common oncogenic variants
M. P. Zafra, D. Alonso-Curbelo, … L. E. Dow·bioRxiv·Nov 20, 2019
- Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells
N. L. Hindul, L. R. Abbott, … K. Tanaka·bioRxiv·Sep 8, 2023
- KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo
A. K. Najumudeen, S. K. Fey, … O. J. Sansom·bioRxiv·Aug 29, 2023
- Reversible Opto-Chemical activation of KRASG12V signaling with near single-cell precision
Luis Manuel Muñoz-Nava, Maria Bespalova, … Philippe I. H. Bastiaens·bioRxiv·Jul 7, 2026
- Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis
Adrien Grimont, David J. Falvo, … Rohit Chandwani·Developmental CellPeer-reviewed·Jul 21, 2026